CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS-Reference-Cited by-同舟云学术

CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS

Published:2021-06-29 Issue:3 Volume:20 Page:5-17
ISSN:2312-3168
Container-title:Siberian journal of oncology
language:
Short-container-title:Sib. onkol. ž.

Author:

Matsko M. V.¹^ORCID,Sklyar S. S.²^ORCID,Ulitin A. Yu.²^ORCID,Matsko D. E.³,Imyanitov E. N.⁴^ORCID,Ievleva A. G.⁵^ORCID,Ni V. I.⁶^ORCID,Volkov N. M.⁷,Zrelov A. A.²^ORCID,Baksheeva A. O.⁸^ORCID,Galkina D. V.⁹

Affiliation:

1. Clinical Scientific-Practical Center of Oncology; Saint-Petersburg State University; Saint-Petersburg Medico-Social Institute

2. Polenov Russian Neurosurgical Institute – the branch of Almazov NMRC

3. Clinical Scientific-Practical Center of Oncology; Saint-Petersburg State University; Saint-Petersburg Medico-Social Institute; Polenov Russian Neurosurgical Institute – the branch of Almazov NMRC

4. I.I. Mechnikov North-Western Medical Uuniversity; N.N. Petrov NMRC of Oncology; Saint-Petersburg State Pediatric Medical University

5. N.N. Petrov NMRC of Oncology; Saint-Petersburg State Pediatric Medical University

6. N.N. Petrov NMRC of Oncology; Sechenov Institute of Evolutionary Physiology and Biochemistry Russian Academy of Sciences

7. Clinical Scientific-Practical Center of Oncology; Saint-Petersburg Medico-Social Institute

8. Children’s city multidisciplinary clinical center of high medical technologies named after K.a. Rauchfusa

9. Saint-Petersburg State University

Publisher

Tomsk Cancer Research Institute

Subject

Cancer Research,Oncology

Reference38 articles.

1. Ostrom Q.T., Gittleman H., Truitt G., Boscia A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol. 2018 Oct 1; 20(suppl_4): iv1–iv86. doi: 10.1093/neuonc/noy131.

2. Noroxe D.S., Poulsen H.S., Lassen U. Hallmarks of glioblastoma: a systematic review. ESMO Open. 2017 Feb 22; 1(6): e000144. doi: 10.1136/esmoopen-2016-000144.

3. Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., WernerWasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J.Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8): 699–708. doi: 10.1056/NEJMoa1308573.

4. Amelot A., De Cremoux P., Quillien V., Polivka M., Adle-Biassette H., Lehmann-Che J., Françoise L., Carpentier A.F., George B., Mandonnet E., Froelich S. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS One. 2015 Jul 9; 10(7): e0130596. doi: 10.1371/journal.pone.0130596.

5. Matsko M.V., Matsko D.E., Volkov N.M., Ulitin A.Yu., Moiseenko V.M., Imyanitov E.N., Iyevleva A.G. Morphologic and molecular features of primary glioblastoma in patients surviving more than 3 years. Siberian Journal of Oncology. 2019; 18(3): 34–44. (in Russian). doi: 10.21294/1814-4861-2019-18-3-34-44.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-free survival after first recurrence in patients with glioblastoma.;Russian Journal for Personalized Medicine;2024-03-22

2. Circulating tumor RNA and exosomes as disease prognosis and therapy effectivity novel markers in case of malignant gliomas in adults;Pediatrician (St. Petersburg);2024-02-22